(Q35159242)

6 August 2017

1 reference

title

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease (English)

1 reference

6 August 2017

cardiovascular disease

1 reference

Samy I McFarlane

1

1 reference

6 August 2017

Ashok Kumar

series ordinal

2

1 reference

6 August 2017

James R Sowers

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

American Journal of Cardiology

6 August 2017

1 reference

6 August 2017

91

1 reference

6 August 2017

12A

1 reference

6 August 2017

30H-37H

1 reference

ACE inhibition in cardiovascular disease

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Diabetes, hypertension, and cardiovascular disease: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

cAMP increases the expression of human angiotensinogen gene through a combination of cyclic AMP responsive element binding protein and a liver specific transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Hypertension, angiotensin II, and oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Angiotensin II signaling in vascular smooth muscle. New concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Noninvasive pulse wave analysis for the early detection of vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

The effect of antihypertensive drugs on vascular compliance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effects of antihypertensive agents on local arterial distensibility and compliance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Lisinopril improves aortic compliance and renal flow. Comparison with nifedipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Different effects of fosinopril and atenolol on wave reflections in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Antihypertensive therapy and the risk of type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Pressor doses of angiotensin II increase hepatic glucose output and decrease insulin sensitivity in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

The effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Potential role of bradykinin in forearm muscle metabolism in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effects of angiotensin-converting enzyme inhibitors on glucose uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Cross-talk between the insulin and angiotensin signaling systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Evolving strategies for renoprotection: diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Clinical practice. Nephropathy in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Add-on angiotensin receptor blockade with maximized ACE inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900432-6

10.1016/S0002-9149(03)00432-6

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference